HLB Life Science Past Earnings Performance
Past criteria checks 2/6
HLB Life Science has been growing earnings at an average annual rate of 27.7%, while the Healthcare industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 0.9% per year. HLB Life Science's return on equity is 1.6%, and it has net margins of 6%.
Key information
27.7%
Earnings growth rate
27.8%
EPS growth rate
| Healthcare Industry Growth | 34.2% |
| Revenue growth rate | 0.9% |
| Return on equity | 1.6% |
| Net Margin | 6.0% |
| Last Earnings Update | 31 Dec 2024 |
Recent past performance updates
We Think Shareholders Should Be Aware Of Some Factors Beyond HLB Life Science's (KOSDAQ:067630) Profit
Mar 27
HLB Life Science (KOSDAQ:067630) Shareholders Should Be Cautious Despite Solid Earnings
May 21Recent updates
The Price Is Right For HLB Life Science Co., Ltd. (KOSDAQ:067630) Even After Diving 41%
Mar 31We Think Shareholders Should Be Aware Of Some Factors Beyond HLB Life Science's (KOSDAQ:067630) Profit
Mar 27Market Participants Recognise HLB Life Science Co., Ltd.'s (KOSDAQ:067630) Revenues
Feb 11Is HLB Life Science (KOSDAQ:067630) A Risky Investment?
Jan 03HLB Life Science Co., Ltd.'s (KOSDAQ:067630) Popularity With Investors Under Threat As Stock Sinks 26%
Oct 24What HLB Life Science Co., Ltd.'s (KOSDAQ:067630) P/S Is Not Telling You
Aug 30HLB Life Science (KOSDAQ:067630) Shareholders Should Be Cautious Despite Solid Earnings
May 21HLB Life Science Co., Ltd.'s (KOSDAQ:067630) 25% Share Price Surge Not Quite Adding Up
Mar 15HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?
Apr 12Did You Participate In Any Of HLB Life Science's (KOSDAQ:067630) Incredible 442% Return?
Feb 14Is HLB Life Science (KOSDAQ:067630) A Risky Investment?
Jan 10We're Not So Sure You Should Rely on HLB Life Science's (KOSDAQ:067630) Statutory Earnings
Dec 06Revenue & Expenses Breakdown
How HLB Life Science makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 24 | 102,240 | 6,138 | 11,103 | 5,177 |
| 30 Sep 24 | 97,109 | 71,046 | 16,410 | 5,768 |
| 30 Jun 24 | 92,870 | -9,205 | 16,732 | 5,732 |
| 31 Mar 24 | 90,719 | 125,455 | 16,624 | 5,749 |
| 31 Dec 23 | 97,990 | -5,983 | 16,104 | 5,454 |
| 30 Sep 23 | 101,918 | -74,410 | 13,463 | 4,670 |
| 30 Jun 23 | 120,360 | -46,626 | 13,291 | 4,679 |
| 31 Mar 23 | 114,798 | -30,251 | 11,973 | 4,274 |
| 31 Dec 22 | 99,591 | -54,277 | 10,665 | 4,349 |
| 30 Sep 22 | 87,628 | -56,700 | 10,098 | 4,008 |
| 30 Jun 22 | 61,067 | -20,834 | 8,319 | 3,759 |
| 31 Mar 22 | 58,848 | -44,045 | 8,208 | 4,316 |
| 31 Dec 21 | 53,494 | -49,152 | 7,954 | 3,846 |
| 30 Sep 21 | 57,296 | -28,397 | 7,882 | 3,087 |
| 30 Jun 21 | 62,917 | -63,998 | 7,936 | 2,704 |
| 31 Mar 21 | 70,598 | -45,888 | 7,534 | 1,526 |
| 31 Dec 20 | 91,797 | -55,797 | 7,637 | 1,431 |
| 30 Sep 20 | 102,427 | 3,809 | 9,142 | 1,124 |
| 30 Jun 20 | 112,471 | -20,064 | 9,622 | 1,188 |
| 31 Mar 20 | 118,918 | -26,267 | 9,722 | 1,464 |
| 31 Dec 19 | 114,019 | -7,605 | 9,667 | 1,429 |
| 30 Sep 19 | 111,639 | -43,329 | 9,765 | 1,703 |
| 30 Jun 19 | 107,874 | -31,166 | 9,692 | 1,804 |
| 31 Mar 19 | 105,435 | -23,689 | 10,313 | 1,630 |
| 31 Dec 18 | 102,476 | -18,191 | 10,501 | 1,321 |
| 30 Sep 18 | 105,040 | 9,936 | 8,058 | 940 |
| 30 Jun 18 | 103,643 | 9,613 | 6,857 | 549 |
| 31 Mar 18 | 106,930 | 6,681 | 5,138 | 298 |
| 31 Dec 17 | 106,445 | 7,761 | 3,967 | 243 |
| 30 Sep 17 | 108,191 | 564 | 4,548 | 252 |
| 30 Jun 17 | 84,642 | -906 | 4,702 | 163 |
| 31 Mar 17 | 59,517 | -1,174 | 4,604 | 81 |
| 31 Dec 16 | 42,234 | -1,251 | 3,986 | 81 |
| 30 Sep 16 | 20,970 | -8,003 | 4,474 | 288 |
| 30 Jun 16 | 25,730 | -8,880 | 3,856 | 307 |
| 31 Mar 16 | 29,191 | -15,904 | 4,538 | 346 |
| 31 Dec 15 | 27,323 | -17,041 | 4,818 | 352 |
| 30 Sep 15 | 29,034 | -10,493 | 3,586 | -5 |
| 30 Jun 15 | 34,740 | -7,677 | 3,956 | -24 |
| 31 Mar 15 | 36,580 | 44 | 3,280 | 30 |
| 31 Dec 14 | 36,560 | 1,331 | 3,174 | 24 |
| 30 Sep 14 | 26,921 | -1,595 | 2,914 | 93 |
| 30 Jun 14 | 27,651 | -2,417 | 3,087 | 93 |
Quality Earnings: A067630 has a large one-off gain of ₩37.5B impacting its last 12 months of financial results to 31st December, 2024.
Growing Profit Margin: A067630 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A067630 has become profitable over the past 5 years, growing earnings by 27.7% per year.
Accelerating Growth: A067630 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: A067630 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (7.7%).
Return on Equity
High ROE: A067630's Return on Equity (1.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/16 13:11 |
| End of Day Share Price | 2025/04/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HLB Life Science Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.